A5072292498- HIV/AIDS drug development and treatment
- Reproductive Health and Technologies
- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV-related health complications and treatments
- Social Policies and Family
- Health, Medicine and Society
- Hepatitis C virus research
- Migration, Identity, and Health
- Multiculturalism, Politics, Migration, Gender
- Psychoanalysis and Psychopathology Research
- Ethics in medical practice
- HIV, Drug Use, Sexual Risk
- Tuberculosis Research and Epidemiology
- Sexual Differentiation and Disorders
- LGBTQ Health, Identity, and Policy
- Assisted Reproductive Technology and Twin Pregnancy
- Ethics in Clinical Research
- Conflict of Laws and Jurisdiction
- Liver Disease Diagnosis and Treatment
- Healthcare Systems and Practices
- Hepatitis B Virus Studies
- Organ Donation and Transplantation
- Homicide, Infanticide, and Child Abuse
- Education, sociology, and vocational training
Institut des sciences juridique et philosophique de la Sorbonne
2018-2024
Université Paris 1 Panthéon-Sorbonne
2008-2024
Centre National de la Recherche Scientifique
2006-2024
Assistance Publique – Hôpitaux de Paris
2021-2024
Université Paris-Saclay
2024
Bicêtre Hospital
2018-2023
Centre de recherches et d’études sur les droits fondamentaux
2019-2023
Université Paris Cité
2006-2020
Éditions Gallimard (France)
2019
Bordeaux Population Health
2019
Abstract Introduction Although weight gain has been reported with the use of integrase strand transfer inhibitors (InSTI), concurrent tenofovir alafenamide (TAF) implicated in recent studies. This study examined changes people living HIV (PLWH) who switched from disoproxil fumarate (TDF) to TAF, clarify relative contribution core agents versus TDF TAF switch. Methods Antiretroviral‐experienced, virologically suppressed PLWH U.S. OPERA cohort were included if they (5NOV2015‐28FEB2019) and...
Background The accurate diagnosis of TB in HIV-infected patients, particularly with advanced immunosuppression, is difficult. Recent studies indicate that a lipoarabinomannan (LAM) assay (Clearview-TB®-ELISA) may have some utility for the patients; however, precise subgroup benefit from this technology requires clarification. LAM sputum samples has, hitherto, not been evaluated. Methods was measured and urine obtained 500 consecutively recruited ambulant suspected TB, 2 primary care clinics...
The first complete long-acting antiretroviral therapy (ART) regimen, cabotegravir + rilpivirine (CAB RPV LA) injectable, was approved in the US for HIV-1 treatment individuals on a stable regimen with viral load < 50 copies/mL, no failure history, and resistance to either or rilpivirine. We describe injection schedule adherence virologic effectiveness of CAB LA routine clinical care US. From OPERA® cohort, all adults HIV who received their ≥ 1 continuation injections between 21 January 2021...
There is growing evidence that tobacco smoking an important risk factor for tuberculosis (TB). are no data validating the accuracy of self-reported in TB patients and limited about prevalence from high-burden settings. We performed a cross-sectional analysis 500 with suspected Cape Town, South Africa. All underwent comprehensive diagnostic testing. The their status was determined against serum cotinine levels. Of 424 included study, 56 60% those active latent infection (LTBI), respectively,...
Marijuana smoking is common and believed to relieve many symptoms, but daily use has been associated with liver fibrosis in cross-sectional studies. We aimed estimate the effect of marijuana on disease progression a Canadian prospective multicenter cohort human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected persons.Data were analyzed for 690 HCV polymerase chain reaction positive (PCR-positive) individuals without significant or end-stage (ESLD) at baseline. Time-updated Cox...
Although interferon-γ release assays (IGRAs) are intended for diagnosing latent tuberculosis (TB), we hypothesised that in a high-burden setting: 1) the magnitude of response when using IGRAs can distinguish active TB from other diagnoses; 2) may aid diagnosis smear-negative TB; and 3) could be useful as rule-out tests TB. We evaluated accuracy two (QuantiFERON®-TB Gold In-tube (QFT-GIT) T-SPOT®. ) 395 patients (27% HIV-infected) with suspected Cape Town, South Africa. IGRA sensitivity...
HLA-B*57:01 screening was added to clinical care guidelines in 2008 reduce the risk of hypersensitivity reaction from abacavir. The uptake and incidence were assessed a prospective cohort United States evaluate effectiveness this intervention. We included all patients initiating an abacavir-containing regimen for first time pre-HLA-B*57:01 period (January 1, 1999 June 14, 2008) or post-HLA-B*57:01 (June 15, January 2016). Yearly both physician panel-adjudicated reactions calculated compared....
In couples who have chosen and confirmed the fate of surplus frozen embryos, which factors influence their decision, with a special emphasis on symbolic representation embryo(s)? Embryo gamete donation use significantly cryopreserved embryos. Previous studies report difficulties for to decide whether or not continue storing embryo(s) different been already highlighted including embryo conceptualization, information support provided by medical institution, quality life events. Little is...
Increases in lipids have been observed people with HIV (PWH) switching from tenofovir disoproxil fumarate (TDF) to alafenamide (TAF). We assessed changes low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) following a switch TDF TAF.Adults ≥1 lipid measure before after TAF were identified the OPERA cohort. Multivariable linear regression using generalized estimating equations was used estimate predicted over time on TAF, modeled flexibly splines.A total of 6451 PWH switched...
Approximately 20% of newly diagnosed people with HIV (PWH) in the United States have advanced infection, yet literature on current antiretroviral therapy (ART) options is limited. The discontinuation/modification and effectiveness common regimens were compared among ART-naïve infection (CD4 cell count <200 cells/μL).ART-naïve adults initiating bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or a boosted darunavir (bDRV)-, dolutegravir (DTG)-, elvitegravir/cobicistat (EVG/c)-based...
Multi-class resistance, intolerance, and drug-drug interactions can result in unique antiretroviral (ART) combinations for heavily treatment-experienced (HTE) people living with HIV (PLWH). We aimed to compare clinical outcomes between HTE non-HTE PLWH.Eligible ART-experienced PLWH care the OPERA® Cohort were identified a cross-sectional manner on December 31, 2016 observed from date of initiation ART regimen taken until loss follow up, death, study end (December 2018), or becoming (non-HTE...
Abstract Background Cabotegravir + rilpivirine (CAB+RPV) injections, the first complete long-acting (LA) antiretroviral therapy (ART) regimen, was approved by FDA in January 2021 for ART-experienced people with HIV (PWH) who are virologically suppressed (VL &lt; 50 copies/mL). Among individuals non-suppressed ≥ 30 copies/mL) at initiation, high rates of virologic suppression were observed demonstration project Ward 86 CAB+RPV LA. We LA real-world utilization and effectiveness over 2...
Abstract Background Cabotegravir long-acting (CAB LA) pre-exposure prophylaxis (PrEP) consists of 2 initiation injections given 1 month apart, followed by a continuation injection every months, with HIV testing before each injection. We compared characteristics CAB LA and oral PrEP users described patterns dosing testing. Methods All individuals ≥12 years old new or ≥1 from 21Dec2021-30Jun2023 in the OPERA cohort were included. was completed if first received ≤60 days apart. Patterns...
Abstract Objectives Our objective was to compare the immunological responses commonly used antiretroviral therapy (ART) regimens among people with advanced HIV in USA and assess virological outcomes regimen persistence. Methods This study included ART‐naïve adults infection (CD4 cell count <200 cells/μL) initiating ART bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), boosted darunavir (bDRV), dolutegravir (DTG), or elvitegravir (EVG/c)‐containing between 1 January 2018 31...
To estimate the prevalence of HIV drug resistance over time and identify risk factors for multiclass resistance.Prospective clinical cohort HIV-infected patients at University North Carolina.Among antiretroviral therapy (ART)-experienced in care 2000-2016, we estimated annual prevalences cumulative resistance, defined as least one major mutation by class. Clinical data multiple imputation were used when genotypic missing, mutations carried forward time. We odds ratios comparing...
Background: Double-dose raltegravir is recommended in HIV1infected patients with tuberculosis.A previous phase 2 study showed similar efficacy of standard 400 mg BID, 800 or efavirenz-based regimens.We aimed to assess noninferiority BID efavirenz HIV1-infected tuberculosis.Methods: ANRS 12300 Reflate TB2 an open-label, 3, randomized trial conducted Brazil, Côte d'Ivoire, France, Mozambique, and Vietnam.ART-na€ ıve aged ≥18 years on tuberculosis treatment for weeks were (1:1) receive 600 QD...
With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess association between ART regimens and changes in body mass index (BMI) ART-experienced, virologically suppressed PLWH. PLWH ≥18 years age Observational Pharmacoepidemiology Research Analysis (OPERA) cohort were included for if prescribed a new regimen containing one following core agents:...
Abstract Background. Tobacco smoking has been shown to be an independent risk factor for liver fibrosis in hepatitis C virus (HCV) infection some cross-sectional studies. No longitudinal study confirmed this relationship, and the effect of tobacco exposure on human immunodeficiency (HIV)-HCV coinfected individuals is unknown. Methods. The population consisted participants from Canadian Co-infection Cohort (CTN 222), a multicenter HIV-HCV 2003 2014. Data were analyzed all who did not have...
Several approaches to clinical ethics consultation (CEC) exist in medical practice and are widely discussed the literature; different models of CECs classified according their methods, goals, consultant's attitude. Although "facilitation" model has been endorsed by American Society for Bioethics Humanities (ASBH) is described an influential manual, alternative approaches, such as advocacy, moral expertise, mediation, engagement practiced defended field. Our Clinical Ethics Center Paris was...